Search Browse Earnings

TScan Therapeutics, Inc. — SlamSEC

TScan Therapeutics, Inc.

Nasdaq:TCRX

Biological Products, (No Diagnostic Substances)·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$2.8M

-86.6% YoY

FY 2025

Adj. EBITDA

-$130.7M

-4642.1% margin

FY 2025

Net Income

-$127.5M

-4527.7% margin

FY 2025

EPS (Diluted)

-$1.14

FY 2025

Stock Price

$1.24

+7.8%

2026-03-09

52W Range

$0.88 – $2.57

P/E Ratio

-1.1x

Market Cap

$29.7M

Cash

$178.7M

FY 2025

Total Debt

$32.1M

FY 2025

Net Cash

$146.6M

FY 2025

Enterprise Value

-$116.9M

Debt / EBITDA

1.1x

FY 2025

EV / EBITDA

0.9x

Employees

—